Sepsis pp 349-356 | Cite as

Tumor Necrosis Factor-Neutralization with a Specific Monoclonal Antibody

  • M. Kluge
  • M. Kaul
Part of the Update in Intensive Care and Emergency Medicine book series (UICM, volume 18)


Sepsis is a clinical condition which represents a systemic response to infection. It has been described for more than 40 years [1]. In spite of significant advances in antimicrobial therapy, lethality of this disease is still high, and septic shock is still estimated to account for about 100000 deaths in the USA annually [2]. During recent years the involvement of both humoral pathways and the cytokine network of the host and their interaction with cellular mechanisms in the induction of the clinical symptoms and consequences of sepsis have gained major scientific attention [3]. The interruption of the endogenous inflammatory cascade has become a novel approach for the treatment of sepsis and septic shock [4].


Septic Shock Systemic Inflammatory Response Syndrome Specific Monoclonal Antibody Murine Monoclonal Antibody Increase Body Temperature 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Waisbren BA (1951) Bacteremia due to gram-negative bacilli other than salmonella: a clinical and therapeutic study. Arch Intern Med 88:467CrossRefGoogle Scholar
  2. 2.
    Parillo JE (1990) Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction and therapy. Ann Intern Med 113:227Google Scholar
  3. 3.
    Glauser MP, Zanetti G, Baumgartner JD, Cohen J (1991) Septic shock: pathogenesis. Lancet 338:732PubMedCrossRefGoogle Scholar
  4. 4.
    Dinarello CA, Gelfand JA, Wolff SM (1993) Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 269:1829PubMedCrossRefGoogle Scholar
  5. 5.
    Tracey KJ, Vlassara H, Cerami A (1989) Cachectin tumor necrosis factor. Lancet ii:1122CrossRefGoogle Scholar
  6. 6.
    Waage A, Halstensen A, Espevik T (1987) Association between tumour necrosis factor in severe and fatal outcome in patients with meningococcal disease. Lancet i:355CrossRefGoogle Scholar
  7. 7.
    Debets JMH, Kampmeijer R, van der Linden PMH et al (1989) Plasma tumour necrosis factor and mortality in critically ill septic patients. Crit Care Med 17:489PubMedCrossRefGoogle Scholar
  8. 8.
    Cohen J, Glauser MP (1991) Septic shock treatment. Lancet 338:736PubMedCrossRefGoogle Scholar
  9. 9.
    Möller A, Emling F, Blohm D et al (1990) Monoclonal antibodies to tumour necrosis factor alpha: in vitro and in vivo application. Cytokine 2:162PubMedCrossRefGoogle Scholar
  10. 10.
    Hirai M, Okamura N, Terano Y et al (1987) Production and characterisation of monoclonal antibodies to human tumor necrosis factor. J Immunol Methods 96:57PubMedCrossRefGoogle Scholar
  11. 11.
    Meager A, Parti S, Leung H et al (1987) Preparation and characterisation of monoclonal antibodies directed against antigenic determinants of recombinant human tumour necrosis factor. Hybridoma 6:305PubMedCrossRefGoogle Scholar
  12. 12.
    Liang CM, Liang SM, Jost T et al (1986) Production and characterisation of monoclonal antibodies against recombinant human tumor necrosis factor/cachectin. Biochem Biophys Res Commun 137:847PubMedCrossRefGoogle Scholar
  13. 13.
    Fendly BM, Toy KJ, Creasey AA et al (1987) Murine monoclonal antibodies defining neutralizing epitopes on tumor necrosis factor. Hybridoma 6:359PubMedCrossRefGoogle Scholar
  14. 14.
    Shimamoto Y, Chen RI, Bollon A et al (1988) Monoclonal antibodies against human recombinant tumor necrosis factor. Immunol Lett 17:311PubMedCrossRefGoogle Scholar
  15. 15.
    Beutler BA, Milsark IW, Cerami A (1985) Cachectin/tumor necrosis factor: production, distribution and metabolic fate in vivo. J Immunol 135:3972PubMedGoogle Scholar
  16. 16.
    Natanson C, Eichenholz PW, Danner RL et al (1989) Endotoxin and tumour necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med 169:823PubMedCrossRefGoogle Scholar
  17. 17.
    Calandra T, Baumgartner JD, Grau GE et al (1990) Prognostic values of tumour necrosis factor/cachectin, interleukin-1, alpha-interferon and gamma-interferon in the serum of patients with septic shock. J Infect Dis 161:982PubMedCrossRefGoogle Scholar
  18. 18.
    Saravolatz LD, Pokriefka RA, Markowitz N (1993) Monoclonal antibodies against TNF: a non-antibiotic strategy for the treatment of sepsis. In: Vincent JL (ed) Yearbook of intensive care and emergency medicine. Springer, Berlin-Heidelberg-New York, pp 100Google Scholar
  19. 19.
    Eskandari MK, Bolgos G, Miller C et al (1992) Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol 148:2724PubMedGoogle Scholar
  20. 20.
    Bone RC (1993) Monoclonal antibodies to tumor necrosis factor in sepsis: help or harm?. Crit Care Med 21:311PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • M. Kluge
  • M. Kaul

There are no affiliations available

Personalised recommendations